Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WESTLAKE VILLAGE, CALIF., MAY 08, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED THE GRANT OF AN AGGREGATE OF 269,000 RESTRICTED STOCK UNITS OF ARCUTIS' COMMON STOCK AS WELL AS OPTIONS TO PURCHASE AN AGGREGATE OF 70,000 SHARES OF ARCUTIS' COMMON STOCK TO 40 NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF MAY 1, 2026, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Q1 2026 NET PRODUCT REVENUE FOR ZORYVE (ROFLUMILAST) WAS $105.4 MILLION, A 65% INCREASE COMPARED TO Q1 2025, AND A 17% DECREASE COMPARED TO Q4 2025 CONTINUED STRONG DEMAND FOR ZORYVE DESPITE TYPICAL Q1 SEASONALITY, WITH CONTINUED GROWTH IN SHARE OF BRANDED NON-STEROIDAL TOPICAL TREATMENTS SUBMITTED SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR ZORYVE CREAM 0.05% TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO EXPAND THE INDICATION FOR THE TREATMENT OF ATOPIC DERMATITIS IN INFANTS AGES 3 TO 24 MONTHS COMPLETED ENROLLMENT IN ZORYVE FOAM 0.3% MAXIMUM USAGE SYSTEMIC EXPOSURE (MUSE) TRIAL IN CHILDREN WITH PLAQUE PSORIASIS OF THE SCALP AND BODY AGES 2 TO 11 YEARS INITIATED PHASE 1A/1B, FIRST-IN-HUMAN STUDY TO EVALUATE SAFETY AND TOLERABILITY FOR INVESTIGATIONAL ARQ-234 IN HEALTHY VOLUNTEERS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS COMPLETED EXPANSION OF DERMATOLOGY SALES FORCE AT THE BEGINNING OF MAY, AND INITIATED THE BUILD-OUT OF A PRIMARY CARE AND PEDIATRICS-FOCUSED ORGANIZATION INCLUDING THE HIRING OF THE HEAD OF PRIMARY CARE FRANCHISE MAINTAINED POSITIVE OPERATING CASH FLOW FOR THE QUARTER WESTLAKE VILLAGE, CALIF., MAY 06, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE.

ARCUTIS ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SUBMISSION SUPPORTED BY DATA FROM INTEGUMENT-INFANT PHASE 2 OPEN-LABEL STUDY IN INFANTS AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS ONCE-DAILY ZORYVE CREAM WAS WELL TOLERATED WITH A SAFETY PROFILE CONSISTENT WITH THAT IN OLDER CHILDREN AND ADULTS ATOPIC DERMATITIS IMPACTS 1 MILLION CHILDREN UNDER THE AGE OF 2 IN THE UNITED STATES ONLY ONE OTHER FDA-APPROVED TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY AGENT AVAILABLE FOR THIS VULNERABLE POPULATION WESTLAKE VILLAGE, CALIF., APRIL 27, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE SUBMISSION OF A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) SEEKING TO EXPAND THE INDICATION FOR ZORYVE (ROFLUMILAST) CREAM 0.05% TO INCLUDE THE TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN INFANTS DOWN TO 3 MONTHS.

ARCUTIS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO THE FDA FOR ZORYVE (ROFLUMILAST) CREAM 0.05% TO EXPAND INDICATION FOR TREATMENT OF ATOPIC DERMATITIS TO INFANTS DOWN TO 3 MONTHS

STRONG RECOMMENDATION WITH HIGH CERTAINTY OF CLINICAL EVIDENCE UNDERSCORES PROVEN EFFICACY, SAFETY, AND TOLERABILITY OF ZORYVE CREAM AS A STEROID-FREE TOPICAL PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITOR ATOPIC DERMATITIS AFFECTS APPROXIMATELY 9.6 MILLION CHILDREN IN THE UNITED STATES WESTLAKE VILLAGE, CALIF., APRIL 22, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT ZORYVE (ROFLUMILAST) CREAM HAS RECEIVED A STRONG RECOMMENDATION, WITH HIGH CERTAINTY OF CLINICAL EVIDENCE, IN THE AMERICAN ACADEMY OF DERMATOLOGY (AAD) CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF PEDIATRIC ATOPIC DERMATITIS.

ARCUTIS' ZORYVE (ROFLUMILAST) CREAM RECEIVES STRONG RECOMMENDATION IN AMERICAN ACADEMY OF DERMATOLOGY FIRST-EVER PEDIATRIC ATOPIC DERMATITIS GUIDELINES

WESTLAKE VILLAGE, CALIF., APRIL 15, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.(NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT IT WILL REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON WEDNESDAY, MAY 6, 2026 AFTER THE U.S. FINANCIAL MARKETS CLOSE.

ARCUTIS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON MAY 6, 2026

MR. TAYLOR BRINGS A STRONG TRACK RECORD LAUNCHING MULTIPLE HIGH-PROFILE THERAPIES, MOST RECENTLY SERVING AS SENIOR VICE PRESIDENT, SALES AT ARCUTIS BIOTHERAPEUTICS (NASDAQ: ARQT), WHERE HE LED U.S. SALES EFFORTS FOR ZORYVE, A NEXT-GENERATION TOPICAL PDE4 INHIBITOR; PREVIOUSLY, HE HELD LEADERSHIP ROLES AT INCYTE (NASDAQ: INCY) SUPPORTING THE LAUNCH OF OPZELURA

PALVELLA THERAPEUTICS APPOINTS ACCOMPLISHED COMMERCIAL LEADER KENT TAYLOR AS SENIOR VICE PRESIDENT OF SALES

ARCUTIS TODAY ANNOUNCED THAT ARCUTIS MANAGEMENT WILL PRESENT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE, TAKING PLACE APRIL 13-16, 2026.

ARCUTIS MANAGEMENT TO PRESENT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

INVESTIGATIONAL ZORYVE (ROFLUMILAST) CREAM 0.05% WAS WELL TOLERATED WITH SAFETY FINDINGS CONSISTENT WITH PRIOR PEDIATRIC EXPERIENCE IN THE INTEGUMENT PROGRAM ZORYVE CREAM IMPROVED SIGNS AND SYMPTOMS OF MILD TO MODERATE ATOPIC DERMATITIS IN INFANTS AGED 3 MONTHS TO LESS THAN 24 MONTHS OVER FOUR WEEKS CAREGIVERS REPORTED RAPID IMPROVEMENT IN ITCH IN AS LITTLE AS 10 MINUTES IN NEARLY HALF OF INFANTS RESULTS FROM ADDITIONAL STUDIES ACROSS THE ZORYVE PORTFOLIO BEING PRESENTED IN THREE POSTER PRESENTATIONS WESTLAKE VILLAGE, CALIF. AND DENVER, MARCH 28, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED NEW DATA FROM THE INTEGUMENT-INFANT PHASE 2 TRIAL DEMONSTRATING THAT ZORYVE (ROFLUMILAST) CREAM 0.05% REDUCED SIGNS AND SYMPTOMS OF ATOPIC DERMATITIS, THE MOST COMMON FORM OF ECZEMA, IN INFANTS AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS.

ARCUTIS PRESENTS NEW PHASE 2 RESULTS IN INFANTS WITH ATOPIC DERMATITIS IN LATE-BREAKING SESSION TODAY AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING

WESTLAKE VILLAGE, CALIF., AND DENVER, MARCH 18, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT IT WILL PRESENT NEW DATA FROM ITS CLINICAL DEVELOPMENT PROGRAM AND MARKETED ZORYVE (ROFLUMILAST) PORTFOLIO DURING THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETINGTAKING PLACE MARCH 27-31 IN DENVER.

ARCUTIS TO PRESENT NEW CLINICAL DATA IN A LATE-BREAKING PODIUM PRESENTATION AND SCIENTIFIC POSTERS AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING

ZORYVE CREAM 0.05% WAS SAFE AND WELL-TOLERATED, WITH EFFICACY THAT WAS MAINTAINED AND IMPROVED OVER TIME UP TO 56 WEEKS OF TREATMENT CHILDREN AGES 2-5 WHO ACHIEVED DISEASE CLEARANCE AND WHO SWITCHED TO PROACTIVE TWICE-WEEKLY APPLICATION SUSTAINED DISEASE CONTROL FOR A MEDIAN DURATION OF ~8 MONTHS THESE RESULTS FURTHER SUPPORT THE COMPANY'S FOCUS ON EXPANDING OPTIONS FOR PEDIATRIC POPULATIONS WESTLAKE VILLAGE, CALIF., MARCH 10, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT PEDIATRIC DERMATOLOGY PUBLISHED DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION (INTEGUMENT-OLE) STUDY EVALUATING ONCE-DAILY ZORYVE (ROFLUMILAST) CREAM 0.05% IN CHILDREN AGED 2 TO 5 YEARS WITH MILD-TO-MODERATE ATOPIC DERMATITIS.

ARCUTIS ANNOUNCES PUBLICATION OF POSITIVE LONG-TERM SAFETY AND EFFICACY DATA WITH ZORYVE (ROFLUMILAST) CREAM 0.05% FOR TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS IN CHILDREN AGES 25 INPEDIATRIC DERMATOLOGY

Arcutis Biotherapeutics, Inc.

ARQT

Price

Financial Reports

No items found.

Press Releases

Arcutis Biotherapeutics, Inc.

ARQT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ARQT